Insider Selling: Natera (NASDAQ:NTRA) Director Sells $642,535.92 in Stock

Natera, Inc. (NASDAQ:NTRA) Director Rowan Chapman sold 2,964 shares of the firm’s stock in a transaction on Tuesday, June 16th. The shares were sold at an average price of $216.78, for a total value of $642,535.92. Following the sale, the director directly owned 3,124 shares of the company’s stock, valued at $677,220.72. This represents a 48.69% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Natera Price Performance

NASDAQ:NTRA opened at $231.41 on Friday. Natera, Inc. has a one year low of $131.81 and a one year high of $256.36. The company has a market cap of $33.14 billion, a P/E ratio of -141.97 and a beta of 1.56. The firm’s fifty day moving average price is $208.20 and its two-hundred day moving average price is $215.52.

Institutional Investors Weigh In On Natera

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. Reflection Asset Management bought a new position in shares of Natera in the 4th quarter valued at $29,000. Palladiem LLC bought a new stake in shares of Natera during the 4th quarter worth $31,000. Horizon Investments LLC bought a new stake in shares of Natera during the 3rd quarter worth $32,000. International Assets Investment Management LLC boosted its stake in Natera by 132.9% in the first quarter. International Assets Investment Management LLC now owns 170 shares of the medical research company’s stock valued at $35,000 after buying an additional 97 shares in the last quarter. Finally, Bank of Jackson Hole Trust boosted its stake in Natera by 103.8% in the fourth quarter. Bank of Jackson Hole Trust now owns 163 shares of the medical research company’s stock valued at $37,000 after buying an additional 83 shares in the last quarter. 99.90% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

NTRA has been the topic of a number of research reports. Morgan Stanley decreased their price target on shares of Natera from $265.00 to $250.00 and set an “overweight” rating on the stock in a research note on Tuesday, March 3rd. Wall Street Zen downgraded shares of Natera from a “buy” rating to a “hold” rating in a research report on Saturday, May 9th. Weiss Ratings restated a “sell (d-)” rating on shares of Natera in a report on Tuesday, April 21st. BTIG Research decreased their target price on Natera from $260.00 to $250.00 and set a “buy” rating on the stock in a research report on Monday, May 11th. Finally, Evercore reiterated an “outperform” rating and set a $270.00 target price on shares of Natera in a research note on Friday, May 8th. Two equities research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, four have issued a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and an average price target of $256.53.

Natera Company Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.